Clinical Trial Update: MK0457 in Patients With Leukemia (0457-003) [Phase 1]

View source ↗

Summary

Phase 1 trial update for MK-0457 (VX-680) in leukemia patients has completed; the study included chronic myeloid leukemia in blast crisis, acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• VX-680 (MK-0457) (tozasertib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute | Phase 1 | Status: COMPLETED